Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say

Shares of Hims & Hers Health Inc (NYSE:HIMS) are under pressure Tuesday, after the company reported downbeat second-quarter revenues.

The announcement came amid an exciting earnings season. Here are some key analyst takeaways.

BofA Securities analyst Allen Lutz maintained an Underperform rating and price target of $28.

Needham analyst Ryan MacDonald reiterated a Hold rating on the stock.

Check out other analyst stock ratings.

BofA Securities: Hims & Hers Health reported weaker-than-expected results and reiterated its full-year guidance, Lutz said in a note. The company is facing several near-term headwinds, including the absence of growth in its core business, which could exert greater pressure on the GLP-1 (Glucagon-like peptide-1) business, he added.

Hims & Hers ...